These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38382744)

  • 41. Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis.
    Rubini NPM; Ensina LFC; Silva EMK; Sano F; Solé D
    Allergol Immunopathol (Madr); 2019; 47(6):515-522. PubMed ID: 31607407
    [TBL] [Abstract][Full Text] [Related]  

  • 42. What are the effects of omalizumab in refractory chronic spontaneous urticaria?
    López M; Navajas-Galimany L
    Medwave; 2015 Dec; 15 Suppl 3():e6346. PubMed ID: 26731420
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.
    Acar A; Gerceker Turk B; Ertam Sagduyu I; Ceylan C; Ozturk G; Unal I
    Cutan Ocul Toxicol; 2020 Sep; 39(3):249-253. PubMed ID: 32597235
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Are antihistamines still used during omalizumab treatment for chronic spontaneous urticaria?
    Melé-Ninot G; Serra-Baldrich E; Spertino J; Guilarte M; Ribó González P; Lleonart-Bellfill R; Figueras-Nart I; Bonfill-Ortí M; Depreux N; Sala-Cunill A; Bielsa-Marsol I; Baliu-Piqué C; Sanmartín-Novell V; Garcia-Navarro X; Expósito-Serrano V; Garnica-Velandia D; Diaz-Sarrió MC; Gómez-Armayones S; Gich Saladich I; Giménez-Arnau A
    Eur J Dermatol; 2022 Sep; 32(5):629-631. PubMed ID: 36468733
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effective treatment of different phenotypes of chronic urticaria with omalizumab: Case reports and review of literature.
    Kasperska-Zajac A; Jarząb J; Żerdzińska A; Bąk K; Grzanka A
    Int J Immunopathol Pharmacol; 2016 Jun; 29(2):320-8. PubMed ID: 26729404
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recalcitrant chronic urticaria treated with dupilumab: Report of two instances refractory to H1-antihistamines, omalizumab and cyclosporine and brief literature review.
    Errichetti E; Stinco G
    Dermatol Ther; 2021 Mar; 34(2):e14821. PubMed ID: 33506984
    [No Abstract]   [Full Text] [Related]  

  • 47. Clinical experience of a chronic urticaria referral university center.
    Andrade Coelho Dias G; Cunha Coelho F; Filippo P; Lacerda Pedrazzi D; Nogueira Arraes AC; Perelló MI; Chigres Kuschnir F; Costa E
    Eur Ann Allergy Clin Immunol; 2020 May; 52(3):112-120. PubMed ID: 31287262
    [No Abstract]   [Full Text] [Related]  

  • 48. Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience.
    Ensina LF; Valle SO; Juliani AP; Galeane M; Vieira dos Santos R; Arruda LK; Melo JM; de Souza PK; Serpa FS; de Andrade DM; França AT; Campos RA; Camelo-Nunes I; Solé D
    Int Arch Allergy Immunol; 2016; 169(2):121-4. PubMed ID: 27055122
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The response to treatment in chronic spontaneous urticaria depends on how it is measured.
    Weller K; Church MK; Metz M; Hawro T; Ohanyan T; Staubach P; Maurer M
    J Allergy Clin Immunol Pract; 2019; 7(6):2055-2056.e4. PubMed ID: 30731179
    [No Abstract]   [Full Text] [Related]  

  • 50. Evaluation of a Guidelines-Based Approach to the Treatment of Chronic Spontaneous Urticaria.
    Sánchez J; Zakzuk J; Cardona R
    J Allergy Clin Immunol Pract; 2018; 6(1):177-182.e1. PubMed ID: 28709817
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a review.
    Gimenez-Arnau AM; Salman A; Podder I
    Eur J Dermatol; 2024 Feb; 34(1):3-12. PubMed ID: 38557452
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interleukin-33, endothelin-1, and inflammatory parameters in chronic spontaneous urticaria.
    Kulumbegov B; Chikovani T; Gotua M; Kikodze N; Magen E
    Allergy Asthma Proc; 2023 Nov; 44(6):429-435. PubMed ID: 37919851
    [No Abstract]   [Full Text] [Related]  

  • 53. Total IgE and atopic status in patients with severe chronic spontaneous urticaria unresponsive to omalizumab treatment.
    Asero R; Ferrucci S; Casazza G; Marzano AV; Cugno M
    Allergy; 2019 Aug; 74(8):1561-1563. PubMed ID: 30801715
    [No Abstract]   [Full Text] [Related]  

  • 54. Differences between adult and pediatric chronic spontaneous urticaria from a cohort of 751 patients: Clinical features, associated conditions and indicators of treatment response.
    Özçeker D; Can PK; Terzi Ö; Ornek SA; Değirmentepe EN; Kızıltac K; Sarac E; Kocatürk E
    Pediatr Allergy Immunol; 2023 Feb; 34(2):e13925. PubMed ID: 36825740
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Remission of chronic spontaneous urticaria following omalizumab with gradually extended dosing intervals: Real-life data.
    Salman A; Aktas M; Apti Sengun O
    Australas J Dermatol; 2021 Aug; 62(3):398-402. PubMed ID: 34156714
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-life experience in the treatment of solar urticaria: retrospective cohort study.
    Snast I; Lapidoth M; Uvaidov V; Enk CD; Mazor S; Hodak E; Levi A
    Clin Exp Dermatol; 2019 Jul; 44(5):e164-e170. PubMed ID: 30828851
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Positive basophil histamine release assay predicts insufficient response to standard-dosed omalizumab in patients with chronic spontaneous urticaria.
    Baumann K; Jørgensen AR; Sørensen JA; Zhang DG; Ghazanfar MN; Skov PS; Woetmann A; Vestergaard C; Maurer M; Thomsen SF
    Clin Exp Allergy; 2023 Dec; 53(12):1318-1321. PubMed ID: 37771063
    [No Abstract]   [Full Text] [Related]  

  • 58. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
    Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
    Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness and safety of omalizumab in a patient with chronic urticaria and hepatitis C.
    Leiva-Salinas M; Francés L; Marin-Cabanas I; Arribas Granados MP; Silvestre JF
    J Eur Acad Dermatol Venereol; 2015 May; 29(5):1027-8. PubMed ID: 24629127
    [No Abstract]   [Full Text] [Related]  

  • 60. Therapeutic Strategy According to Differences in Response to Omalizumab in Patients With Chronic Spontaneous Urticaria.
    Giménez Arnau AM; Valero Santiago A; Bartra Tomás J; Jáuregui Presa I; Labrador Horrillo M; Miquel Miquel FJ; Ortiz de Frutos J; Sastre J; Silvestre Salvador JF; Ferrer Puga M
    J Investig Allergol Clin Immunol; 2019; 29(5):338-348. PubMed ID: 30222111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.